Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

Elizabeth Knock¹, Krista J Siefried^{1

2

3

4}, Gill Bedi⁵, Steven Albert⁶, Richard O Day⁷, Nadine Ezard^{1

2

3

4}, Margaret Ross⁸, Paul Liknaitzky^{9

10}, Jonathan Brett^{7

11}

Affiliations

¹ St Vincent's Hospital Alcohol and Drug Service, Sydney, New South Wales, Australia.
² The National Centre for Clinical Research on Emerging Drugs of Concern (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia.
³ National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia.
⁴ New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Ministry of Health, Sydney, New South Wales, Australia.
⁵ Centre for Youth Mental Health, Orygen, Parkville, Victoria, Australia.
⁶ School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
⁷ St Vincent's Clinical Campus, University of New South Wales, Sydney, New South Wales, Australia.
⁸ Department of Psychosocial Cancer Care, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
⁹ Department of Psychiatry, School of Clinical Sciences Monash University, Clayton, Victoria, Australia.
¹⁰ School of Psychological Sciences, Monash University, Parkville, Victoria, Australia.
¹¹ School of Population Health, University of New South Wales, Sydney, New South Wales, Australia.

PMID: 40974259
DOI: 10.1111/add.70187

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

Elizabeth Knock et al. Addiction. 2025.

. 2025 Sep 20.

doi: 10.1111/add.70187. Online ahead of print.

Authors

Elizabeth Knock¹, Krista J Siefried^{1

2

3

4}, Gill Bedi⁵, Steven Albert⁶, Richard O Day⁷, Nadine Ezard^{1

2

3

4}, Margaret Ross⁸, Paul Liknaitzky^{9

10}, Jonathan Brett^{7

11}

Affiliations

¹ St Vincent's Hospital Alcohol and Drug Service, Sydney, New South Wales, Australia.
² The National Centre for Clinical Research on Emerging Drugs of Concern (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia.
³ National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia.
⁴ New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Ministry of Health, Sydney, New South Wales, Australia.
⁵ Centre for Youth Mental Health, Orygen, Parkville, Victoria, Australia.
⁶ School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
⁷ St Vincent's Clinical Campus, University of New South Wales, Sydney, New South Wales, Australia.
⁸ Department of Psychosocial Cancer Care, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
⁹ Department of Psychiatry, School of Clinical Sciences Monash University, Clayton, Victoria, Australia.
¹⁰ School of Psychological Sciences, Monash University, Parkville, Victoria, Australia.
¹¹ School of Population Health, University of New South Wales, Sydney, New South Wales, Australia.

PMID: 40974259
DOI: 10.1111/add.70187

Abstract

Background & aims: There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin-assisted psychotherapy for methamphetamine use disorder.

Design: Single arm, open label pilot study.

Setting: Outpatient public stimulant treatment program at St. Vincent's Hospital, Sydney, Australia.

Participants: We recruited 15 participants that were ≥25 years old, seeking treatment for methamphetamine use, using methamphetamine ≥4 days/month at screening, and without serious mental illness or contraindicated medical conditions or medications.

Intervention: Participants received three preparatory psychotherapy sessions over two weeks before a single psilocybin dosing session (25 mg oral), followed by two integration psychotherapy sessions over one week. Psychotherapy included elements of motivational enhancement and acceptance and commitment therapy. Participants were followed for 90 days post psilocybin-assisted psychotherapy session.

Measurements: Primary endpoints were safety (as measured by adverse events over the trial and vital signs during psilocybin dosing) and feasibility (as measured by enrolment and dropout rates), and secondary endpoints included measuring self-reported methamphetamine and other illicit drug use, drug craving, depression, anxiety, stress and quality of life measures.

Findings: Of 56 participants pre-screened, 15 were eligible and enrolled, 14 completed the intervention and 13 completed 90-day post-dose follow-up.". No serious adverse events (AEs) occurred, and the seven treatment related AEs were self-limiting and mild to moderate in severity. AEs included hypertension during the dosing session and headache (n = 4), nausea (n = 1) and noise sensitivity (n = 1) within the week following the dose. Methamphetamine use (over the prior 28 days) was observed to be lower at screening (median 12 days, IQR 7-16, n = 15) relative to day 28 (median 0 days, IQR 0-2, n = 13) and 90 (median 2 days, IQR 1-4, n = 14) post psilocybin. Methamphetamine craving was also observed to be lower while quality of life, depression, anxiety, and stress were observed to be higher at days 28 and 90 follow-up relative to baseline.

Conclusions: Psilocybin assisted psychotherapy for methamphetamine use disorder was feasible to implement in an outpatient setting and did not appear to generate safety concerns. A larger randomised controlled trial is required to confirm efficacy and safety.

Keywords: clinical trial; methampetamine use disorder; outpatient; pilot study; psilocybin assisted psychotherapy; psychedelic.

PubMed Disclaimer

References

REFERENCES

1. World Drug Report 2019 2019.
1. Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, et al. The Australian drug harms ranking study. J Psychopharmacol. 2019;33(7):759–768. https://doi.org/10.1177/0269881119841569
1. van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. 2015;29(6):655–660. https://doi.org/10.1177/0269881115581980
1. Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394(10209):1652–1667. https://doi.org/10.1016/S0140-6736(19)32230-5
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th ed. American psychiatric association; 2022.

Grants and funding

LinkOut - more resources

Full Text Sources
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

Affiliations

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

Authors

Affiliations

Abstract

References

REFERENCES

Grants and funding

LinkOut - more resources

Full Text Sources